Neurotrope Bioscience has entered into a collaboration agreement with Icahn School of Medicine at Mount Sinai to develop Bryostatin-1 in the treatment of Niemann-Pick Type C (NPC) disease.
Under the exclusive licence agreement, Neurotrope Bioscience will use Mount Sinai’s information and data package for the use of bryostatin in treating of NPC disease.
Go deeper with GlobalData
The company said that the licence also covers other diseases and disorders relying on activation of PKCepsilon, an enzyme that is important to the health of certain cells.
Under the agreeement’s terms, Mount Sinai will receive an up-front licensing fee and an annual maintenance fee from Neurotrope Bioscience. Mount Sinai will also receive payments based upon predetermined product development milestones.
In addition, Neurotrope Bioscience will pay Mount Sinai a portion of consideration received from sub-licensees and a royalty on commercial net sales of products.
See Also:
Neurotrope Bioscience is conducting the development programme in partnership with Mount Sinai Genetics and Genomic Sciences Dr Yiannis Ioannou.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOn behalf of itself and Mount Sinai, the company has also applied for a provisional patent in the US to protect their ability to use and commercialise bryostatin technology for this disease indication.
Neurotrope co-chairmen and co-CEOs Paul Freiman and Charles Ramat jointly said: "We are extremely pleased that Mount Sinai and Dr Ioannou wish to participate in this important step in furthering the company’s strategic plan to be involved in orphan diseases which exhibit progressive loss of neurological functions.
"The submission of our joint provisional patent application further supports our belief in the therapeutic potential of bryostatin as an effective therapy in Alzheimer’s and other neurodegenerative diseases."
Niemann-Pick Type C Disease is part of a group of inherited metabolic disorders known as lysosomal storage diseases. It is a rare disease, mostly of children who are afflicted with Alzheimer-like symptoms.
